Skip to main content
OpenTrials
Completed

NCT Number: NCT04041453

Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients

There are four species of intestinal worms collectively known as soil-transmitted helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris lumbricoides (roundworms), and Trichuris trichiura (whipworms). These parasites affect over two billion people and contribute to significant morbidity and disability, especially in high risk groups, for example children, agricultural workers and pregnant women. In children, STH are associated with impaired nutritional status evidenced by stunting, thinness and underweight.

As is the case in most Latin America, STH are a public health problem in Honduras. The World Health Organization (WHO) informs that more than 2.5 million children (under 15 years of age) in the country are at risk of infection. To control these infections Honduras has established a national deworming program that operates since 2001 but despite these efforts, the prevalence of STH infections remains unacceptably high. This is especially true in rural communities where prevalence can be as high as 70% of the children population.

Ivermectin (IVM) in combination with albendazole (ALB) has demonstrated the capacity to improve efficacy compared to any of these drugs in monotherapy; the efficacy is however, still inadequate in terms of cure rate, although egg reduction rates are significant.

The purpose of the current trial is to assess the safety and efficacy of 3 experimental regimens for the treatment of infections by Trichuris trichiura in children in comparison with the current standard of practice in Mass Drug Administration (MDA) campaigns. The experimental regimens will explore the effect of multiple day regimens and high dose ivermectin.

Treatment arms:

* Group 1: single dose of ALB 400 mg. (active control arm). N:39 * Group 2: single dose ALB 400mg + IVM 600µg/Kg. N: 57 * Group 3: daily dose ALB 400mg for 3 consecutive days. N:24 * Group 4: daily dose ALB 400mg + IVM 600µg for 3 consecutive days. N:57

Total Study Population: 177

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

IIET, Orán, Salta Province, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infection with T. trichiura by Kato Katz.
  • Body weight >15kg.
  • Accepts participation

Exclusion criteria

  • Albendazole and/or mebendazol treatment in the previous 3 months.
  • Allergy to the study drugs
  • Acute medical conditions
  • Clinical trial participation in the previous 3 months.
  • Pregnancy.

Treatment and study plan

Ivermectin

Drug

Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.

Albendazole

Drug

Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.

Primary outcomes

  1. Cure Rate

    Time frame: 21 days

    Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.

Secondary outcomes

  1. Egg Change Rate

    Time frame: 21 days

    Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).

  2. Beta Tubulin Resistance

    Time frame: 21days

    Measurement of the incidence of mutations of tubulin in Trichuris trichiura eggs collected pre and post treatment using molecular biology techniques.

    This data is not available yet due to the COVID-19 pandemic, but the data will be available and reported in the future. Anticipated reporting date for this outcome measure is estimated by 2021 and will be confirmed once the pandemic is over.

Sponsors and collaborators

Lead sponsor

Alejandro Krolewiecki

Other

Collaborators

  • Brock University
  • Universidad Nacional Autonoma de Honduras
  • Universidad Nacional del Centro de la Provincia de Buenos Aires

Registry information

Official study title

Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients

Acronym: HI4T

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 1, 2019
Registry last updated
Jul 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.